-transparent.png){kind=logo}
A murine transitional cell carcinoma tumor model has been used to evaluate the combined use of radiotherapy and three chemotherapeutic agents, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and cis-diamminedichloroplatinum. The preliminary radiation therapy evaluation demonstrated that the tumor is radiosensitive. The combined use of cyclophosphamide and radiation therapy was the most effective regimen, especially when the drug was started prior to radiotherapy. Cis-diamminedichloroplatinum and radiation were a lethal combination, but a synergistic effect was produced when the drug was given after completion of radiotherapy. Doxorubicin hydrochloride and radiotherapy may be synergistic, but more evaluation is necessary.
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
January 1984,
Oncology,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
August 1975,
Cancer,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
February 1982,
Urology,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
February 1999,
Hinyokika kiyo. Acta urologica Japonica,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
January 1979,
Transactions of the American Association of Genito-Urinary Surgeons,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
January 1992,
Cancer chemotherapy and pharmacology,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
September 1984,
Hinyokika kiyo. Acta urologica Japonica,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
January 1998,
Cancer surveys,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
June 2012,
Cancer discovery,
T E Weldon, and
E Kursh, and
L J Novak, and
L Persky
January 1988,
European urology,
